ATLANTA--(BUSINESS WIRE)--June 4, 2006--Amgen (NASDAQ:AMGN - News), the world’s largest biotechnology company, announced interim data from two Phase 2 clinical studies of denosumab, an investigational fully human monoclonal antibody that inhibits RANK Ligand. As reported at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), denosumab treatment resulted in a rapid suppression of bone turnover among advanced cancer patients with bone metastases; these results were also sustained at all time points measured in the study.
